CAPECITABINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H22FN3O6
Molecular Weight	359.3501
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O

InChI

InChIKey=GAGWJHPBXLXJQN-UORFTKCHSA-N

InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/xeloda-drug.htm https://www.drugs.com/mtm/capecitabine.html

Capecitabine is a fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered systemic prodrug which is converted to 5-fluorouracil (5-FU). Both normal and tumor cells metabolize 5-FU to 5-fluoro-2’-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2’-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis. Most common adverse reactions (≥30%) were diarrhea, hand-and-foot syndrome, nausea, vomiting, abdominal pain, fatigue/weakness, and hyperbilirubinemia. The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Thymidylate synthase 33 Target ID: CHEMBL1952 Sources: http://www.drugbank.ca/drugs/DB01101 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/16178783 \| https://www.ncbi.nlm.nih.gov/pubmed/1704999 \| https://www.ncbi.nlm.nih.gov/pubmed/25634241 \| https://www.ncbi.nlm.nih.gov/pubmed/8996166	Inhibitor 8504
RNA 19 Target ID: CHEMBL2311222 Sources: http://www.drugbank.ca/drugs/DB01101 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	Interacts 323
Cytidine deaminase 5 Target ID: CHEMBL4502 Sources: https://www.ema.europa.eu/en/documents/scientific-discussion/xeloda-epar-scientific-discussion_en.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/18562256	Substrate 661

Conditions

Condition	Modality	Targets	Highest Phase	Product
Colorectal cancer 102 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	Primary		Approved 8583	XELODA Approved Use Capecitabine tablets, USP are a nucleoside metabolic inhibitor with antineoplastic activity indicated for: • Adjuvant Colon Cancer (1.1) oPatients with Dukes’ C colon cancer • Metastatic Colorectal Cancer (1.1) oFirst-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred • Metastatic Breast Cancer (1.2) oIn combination with docetaxel after failure of prior anthracycline-containing therapy oAs monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen 1.1 Colorectal Cancer •Capecitabine tablets, USP are indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. Capecitabine was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent capecitabine in the adjuvant treatment of Dukes’ C colon cancer. •Capecitabine tablets are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with capecitabine monotherapy. Use of capecitabine instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. 1.2 Breast Cancer •Capecitabine tablets, USP in combination with docetaxel are indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. •Capecitabine tablets monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated (e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents). Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen. Launch Date 1998
Breast cancer 432 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	Primary		Approved 8583	XELODA Approved Use Capecitabine tablets, USP are a nucleoside metabolic inhibitor with antineoplastic activity indicated for: • Adjuvant Colon Cancer (1.1) oPatients with Dukes’ C colon cancer • Metastatic Colorectal Cancer (1.1) oFirst-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred • Metastatic Breast Cancer (1.2) oIn combination with docetaxel after failure of prior anthracycline-containing therapy oAs monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen 1.1 Colorectal Cancer •Capecitabine tablets, USP are indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. Capecitabine was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent capecitabine in the adjuvant treatment of Dukes’ C colon cancer. •Capecitabine tablets are indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with capecitabine monotherapy. Use of capecitabine instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. 1.2 Breast Cancer •Capecitabine tablets, USP in combination with docetaxel are indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. •Capecitabine tablets monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated (e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents). Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen. Launch Date 1998

C_max

Value	Dose	Analyte	Population
9105 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24022189	1000 mg/m² 2 times / day multiple, oral dose: 1000 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	CAPECITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
3515 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29948022	1250 mg/m² 2 times / day multiple, oral dose: 1250 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	.ALPHA.-FLUORO-.BETA.-ALANINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
3035 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24022189	1000 mg/m² 2 times / day multiple, oral dose: 1000 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	CAPECITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
10238 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24022189	1000 mg/m² 2 times / day multiple, oral dose: 1000 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	CAPECITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
45027 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29948022	1250 mg/m² 2 times / day multiple, oral dose: 1250 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	.ALPHA.-FLUORO-.BETA.-ALANINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
4098 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24022189	1000 mg/m² 2 times / day multiple, oral dose: 1000 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	CAPECITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
0.75 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	1250 mg/m² 2 times / day multiple, oral dose: 1250 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	CAPECITABINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
0.78 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24022189	1000 mg/m² 2 times / day multiple, oral dose: 1000 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	CAPECITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.74 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24022189	1000 mg/m² 2 times / day multiple, oral dose: 1000 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:	CAPECITABINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
40% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	1250 mg/m² 2 times / day multiple, oral dose: 1250 mg/m² route of administration: Oral experiment type: MULTIPLE co-administered:		CAPECITABINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2500 mg 2 times / day multiple, oral Highest studied dose Dose: 2500 mg, 2 times / day Route: oral Route: multiple Dose: 2500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18398145	unhealthy, 34-68 Health Status: unhealthy Age Group: 34-68 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/18398145	DLT: Hand-and-foot syndrome, Diarrhea... Dose limiting toxicities: Hand-and-foot syndrome (grade 3, 28.6%) Diarrhea (grade 3, 14.29%) Sources: https://pubmed.ncbi.nlm.nih.gov/18398145
2000 mg 2 times / day multiple, oral MTD Dose: 2000 mg, 2 times / day Route: oral Route: multiple Dose: 2000 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18398145	unhealthy, 41-53 Health Status: unhealthy Age Group: 41-53 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/18398145	DLT: Hand-and-foot syndrome... Dose limiting toxicities: Hand-and-foot syndrome (grade 3, 14.29%) Sources: https://pubmed.ncbi.nlm.nih.gov/18398145
1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	Disc. AE: Coagulopathy, Diarrhea... AEs leading to discontinuation/dose reduction: Coagulopathy Diarrhea Cardiotoxicity Dehydration Renal failure Fetal damage Mucocutaneous disorder (severe) Stevens Johnson syndrome Toxic epidermal necrolysis Hyperbilirubinemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf

AEs

AE	Significance	Dose	Population
Diarrhea	grade 3, 14.29% DLT	2500 mg 2 times / day multiple, oral Highest studied dose Dose: 2500 mg, 2 times / day Route: oral Route: multiple Dose: 2500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18398145	unhealthy, 34-68 Health Status: unhealthy Age Group: 34-68 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/18398145
Hand-and-foot syndrome	grade 3, 28.6% DLT	2500 mg 2 times / day multiple, oral Highest studied dose Dose: 2500 mg, 2 times / day Route: oral Route: multiple Dose: 2500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18398145	unhealthy, 34-68 Health Status: unhealthy Age Group: 34-68 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/18398145
Hand-and-foot syndrome	grade 3, 14.29% DLT	2000 mg 2 times / day multiple, oral MTD Dose: 2000 mg, 2 times / day Route: oral Route: multiple Dose: 2000 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18398145	unhealthy, 41-53 Health Status: unhealthy Age Group: 41-53 Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/18398145
Cardiotoxicity	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf
Coagulopathy	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf
Dehydration	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf
Diarrhea	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf
Fetal damage	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf
Hyperbilirubinemia	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf
Renal failure	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf
Stevens Johnson syndrome	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf
Toxic epidermal necrolysis	Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf
Mucocutaneous disorder	severe Disc. AE	1250 mg/m2 2 times / day multiple, oral Recommended Dose: 1250 mg/m2, 2 times / day Route: oral Route: multiple Dose: 1250 mg/m2, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf

PubMed

Title	Date	PubMed
[The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].	2001	11317529
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.	2001	11306725
The oral fluorinated pyrimidines.	2001	11291832
The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer.	2001	11161228
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.	2001 Aug	11545541
Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.	2001 Dec	11843252
Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.	2001 Dec	11720823
Capecitabine in breast cancer: current status.	2001 Jan	11899351
Capecitabine in colorectal cancer.	2001 Jan	11219977
[Capecitabine in the treatment of colorectal cancer].	2001 Jan-Feb	11300027
The significance of thymidine phosphorylase expression in colorectal cancer.	2001 Jan-Feb	11115583
Xeloda in colorectal cancer.	2001 Jun	11452682
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.	2001 May	11313169
Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.	2001 May 1	11291085
Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same.	2001 Nov 1	11689576
From the Food and Drug Administration.	2001 Nov 7	11694130
Role of thymidine phosphorylase in biomodulation of fluoropyrimidines.	2001 Sep	11530879
[Recent aspects of palliative treatment of metastasized colorectal carcinoma].	2001 Sep 15	11603115
Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience.	2002	11853000
Future treatment options with capecitabine in solid tumours.	2002 Feb	11841932
Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials.	2002 Feb	11841931
An evolving role for oral fluoropyrimidine drugs.	2002 Feb 15	11844808

Patents

Sample Use Guides

In Vivo Use Guide

Take XELODA with water within 30 min after a meal. Monotherapy: 1250 mg/m2 twice daily orally for 2 weeks followed by a one week rest period in 3-week cycles.

Route of Administration: Oral

In Vitro Use Guide

After 48 hours treatment of MCF7 cell line with capecitabine, in the concentration of 1147.9 μg/ml 50% of cells have been inhibited. After 72 hours treatment of the cells with capecitabine, at the concentration of 921 μg/ml 50% of cells have been inhibited.

Name

Type

Language

CAPECITABINE

Official Name

English

CAPECITABINE ACCORD

Preferred Name

English

XELIRI COMPONENT CAPECITIBINE

Common Name

English

CAPECITABINE [VANDF]

Common Name

English

RO-091978000

Code

English

Capecitabine [WHO-DD]

Common Name

English

CAPECITABINE [USP MONOGRAPH]

Common Name

English

CAPECITABINE [JAN]

Common Name

English

Xelox component capecitabine

Common Name

English

CAPECYTABINE

Common Name

English

ECANSYA

Brand Name

English

PENTYL 1-(5-DEOXY-.BETA.-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINECARBAMATE

Common Name

English

CARBAMIC ACID, (1-(5-DEOXY-.BETA.-D-RIBOFURANOSYL)-5-FLUORO-1,2-DIHYDRO-2-OXO-4-PYRIMIDINYL)-, PENTYL ESTER

Common Name

English

CAPECITABINE SUN

Brand Name

English

CAPECITABINE [USP-RS]

Common Name

English

NSC-759853

Code

English

CAPECITABINE [USP IMPURITY]

Common Name

English

CAPECITABINE [EP MONOGRAPH]

Common Name

English

RO-09-1978000

Code

English

CAPECITABINE [MI]

Common Name

English

CAPECITABINE [MART.]

Common Name

English

CAPECITABINE [EMA EPAR]

Common Name

English

CAPIIBINE

Common Name

English

capecitabine [INN]

Common Name

English

XELODA

Brand Name

English

RO 09-1978/000

Code

English

CAPECITABINE TEVA

Brand Name

English

CAPECITABINE MEDAC

Brand Name

English

CAPECITABINE [USAN]

Common Name

English

CAPECITABINE [ORANGE BOOK]

Common Name

English

CAPTABIN

Common Name

English

CAPECITABINE [HSDB]

Common Name

English

CAPECITIBINE

Common Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

CAPECITABINE ACCORD (AUTHORIZED: COLONIC NEOPLASMS, BREAST NEOPLASMS, COLORECTAL NEOPLASMS, STOMACH NEOPLASMS)